You are here: Industry Insights > Dsuvia

News List

AcelRx Announces an Investigator-Initiated Study of Dsuvia in Orthopedic Patients americanpharmaceuticalreview
August 25, 2020
AcelRx Pharmaceuticals has announced an investigator-initiated study with Cleveland Clinic. The study will assess the effects of DSUVIA on post-operative recovery from orthopedic surgery.
FDA controversially approves potent opioid up to ten times stronger than fentanyl pharmafile
November 20, 2018
Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five to ten times stronger than fentanyl
AcelRx Announces FDA Approval of Dsuvia americanpharmaceuticalreview
November 07, 2018
AcelRx Announces FDA Approval of Dsuvia
AcelRx Announces Date of FDA Advisory Committee Meeting for Dsuvia americanpharmaceuticalreview
September 12, 2018
AcelRx Pharmaceuticals announced the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) has planned an Advisory Committee meeting to review the company's New Drug Application (NDA) for Dsuvia for the m
AcelRx Announces FDA Acceptance of NDA for DSUVIA drugs
June 12, 2018
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings
AcelRx resubmits New Drug Application for DSUVIA americanpharmaceuticalreview
May 18, 2018
DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, has a proposed indication for the management of moderate-to-severe acute pain in medically supervised settings,
AcelRx Pharma Plans to Resubmit New Drug Application for Dsuvia biospace
March 12, 2018
AcelRx Pharmaceuticals received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Dsuvia (sufenetanil sublingual tablet) for pain.